LSD analogues, chemical relatives of the mind-altering drug LSD sold as unregulated research chemicals, draw interest for anxiety, problem drinking and longevity. Appeal rests mostly on supervised LSD trials; human analogue data come from a tiny dosing study, surveys and case reports; small repeated doses have not clearly outperformed placebo. Risks: frightening experiences, heart strain, rare lasting loss of touch with reality in vulnerable people, dangerous lithium reactions, mislabelled products. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Resting blood pressure | <120/80 mmHg; dosing deferred at ≥140/90 mmHg | Cardiovascular strain |
| Resting heart rate | 50–70 beats/min; dosing deferred if >100 | Stimulation, arrhythmia risk |
| QTc interval on ECG (heart electrical tracing) | <430 ms (men), <450 ms (women) | Heart rhythm safety |
| Heart valve echocardiogram (heart ultrasound) | No valve leakage or thickening | Heart valve risk |
| ALT (liver enzyme) | <25 U/L | Liver clearance capacity |
| GAD-7 anxiety score | <5 | Anxiety response |
| PHQ-9 depression score | <5 | Depression response |
| CYP2D6 genotype | Normal metabolizer | Predicts exposure and duration |
Cadence: Baseline before starting; blood pressure and heart rate before dosing and at 2–3 hours on each dosing day; symptom questionnaires at 1, 4 and 12 weeks after a full-dose session; blood pressure, heart rate and liver enzymes every 3–6 months during repeated use; echocardiogram every 12 months for microdosing beyond 6 months